The acquisition significantly strengthens Abbott's position in high-growth cancer diagnostics. Traders should monitor integration progress and synergy realization. The deal may lead to upward revisions in Abbott's long-term growth guidance.
Price Chart
Executive Summary
Abbott Laboratories completed the acquisition of Exact Sciences for $105.00 per share in cash, establishing Abbott as a leader in cancer screening and diagnostics. The deal adds Exact Sciences' portfolio, including Cologuard and Oncotype DX, to Abbott's diagnostics business.
Key Facts
- Abbott completed the acquisition of Exact Sciences on March 23, 2026
- Exact Sciences shareholders received $105.00 per share in cash
- Exact Sciences is now a wholly owned subsidiary of Abbott
- The deal establishes Abbott as a leader in the $60 billion U.S. cancer screening and precision oncology diagnostics market
- Key products acquired include Cologuard, Oncotype DX, Oncodetect, and Cancerguard
Financial Impact
Total deal value approximately $13.7 billion based on Exact Sciences' ~130 million shares outstanding at $105/share
Risk Factors
- Integration challenges between the two organizations
- Failure to realize anticipated synergies
- Regulatory or operational hurdles in combining the businesses
- Potential dilution of Abbott's earnings in the near term
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-033079 |
| Document: tm268709d2_ex99-1.htm | 0001104659-26-033079 |
| Document: 0001104659-26-033079-index-headers.html | 0001104659-26-033079 |
| Document: 0001104659-26-033079-index.html | 0001104659-26-033079 |
| Document: 0001104659-26-033079.txt | 0001104659-26-033079 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 today | ANALYST-UPGRADE | $98.00 awaiting T+5 | awaiting T+5 | — | $96.30 (−1.73%) |
Sep 14, 2026 18d ago | Court Ruling | $103.09 $102.98 | ▼ −0.11% | ▼ −1.77% | $96.30 (−6.59%) |
Aug 11, 2026 7w ago | Court Ruling | $109.72 $112.68 | ▲ +2.70% | ▲ +3.10% | $96.30 (−12.23%) |
Aug 11, 2026 7w ago | Court Ruling | $109.72 $112.68 | ▲ +2.70% | ▲ +3.10% | $96.30 (−12.23%) |
Jul 31, 2026 9w ago | Institutional Cluster | $105.70 $107.81 | ▲ +2.00% | ▼ −1.51% | $96.30 (−8.89%) |
Jul 31, 2026 9w ago | Court Ruling | $105.70 $107.81 | ▲ +2.00% | ▼ −1.51% | $96.30 (−8.89%) |
Jul 24, 2026 10w ago | Court Ruling | $103.06 $105.61 | ▲ +2.47% | ▲ +2.10% | $96.30 (−6.56%) |
Jul 16, 2026 11w ago | 8-K | $98.83 $100.75 | ▲ +1.94% | ▲ +3.61% | $96.30 (−2.56%) |
Jul 14, 2026 11w ago | Court Ruling | $88.96 $101.66 | ▲ +14.28% | ▲ +15.57% | $96.30 (+8.25%) |
Jul 7, 2026 12w ago | Court Ruling | $95.84 $88.96 | ▼ −7.18% | ▼ −7.73% | $96.30 (+0.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access